|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded |
Company Size: |
50 Employees In BC (50 Total)
50 In BC (50 Total)
|
Year Founded: |
2005 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
development, commercialization, reprofiling, drugs, Diabetic Macular Edema
|
Profile Views: |
1,221 Company Profile Views |
|
|
iCo Therapeutics is a "Search and Development" company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development of these therapeutics may include drug delivery technologies-such as sustained release or biodegradable matrices to extend patent coverage.
There is a significant decrease in development risk associated with targeting existing drugs, including:
- Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
- Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
- The target and mechanism of action has been identified.
|
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
Want More iCo Therapeutics Inc. News? 1 2
|
Next »
|
|
|
|
|
Jan 6, 2021
|
iCo Therapeutics Announces $US 550,000 Joint Development of iCo-019 with Skymount Medical
|
Apr 16, 2020
|
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
|
Mar 11, 2020
|
iCo Therapeutics Announces Leadership Changes
|
Feb 11, 2020
|
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
|
Dec 30, 2019
|
iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
|
Nov 25, 2019
|
iCo Therapeutics Partners with Top 15 Biotech Company Alexion Pharmaceuticals for the Development and Commercialization of iCo-008
|
Aug 19, 2019
|
iCo Therapeutics Inc. Announces Closing of $2.1 Million Private Placement Financing
|
Feb 21, 2019
|
iCo Therapeutics Inc. Announces $1.25 Million Non-Brokered Private Placement Financing
|
Nov 21, 2018
|
iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
|
Nov 13, 2018
|
iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
|
|
1 - 10 of 32 results
|
|
 |
|
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|